⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
417 patients with HER2+ breast cancer randomized to 4 neoadjuvant regimens (trastuzumab+docetaxel, pertuzumab+trastuzumab+docetaxel, pertuzumab+trastuzumab, pertuzumab+docetaxel). At 5 years: PFS 81%, 86%, 73%, 73% respectively. PFS and DFS support pathological complete response as early indicator of long-term outcome. No new safety concerns. Funded by F. Hoffmann-La Roche.
Coeff. authors = avg(0.40, 0.70) = 0.55
Coeff. editorial = avg(0.90, 0.90) = 0.90
min(0.55, 0.90) = 0.55← lowest dominates
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Final coefficient : 0.55
Final score = 44.5/52.8 × 0.55 × 100 = 46/100
The benefits and harms of breast cancer screening: an independent review.
Marmot MG — 2012 · Lancet (London, England)
Contrasted resultsCirculating tumor cells, disease progression, and survival in metastatic breast cancer.
Cristofanilli M — 2004 · The New England Journal of Medicine
Contrasted resultsEfficacy of bilateral prophylactic mastectomy in women with a family history of breast …
Hartmann LC — 1999 · The New England journal of medicine
Contrasted resultsBreast cancer and hormone-replacement therapy in the Million Women Study.
Beral V — 2003 · Lancet
Contrasted resultsAverage risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations det…
Antoniou A — 2003 · American journal of human genetics